Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071622 | 0.86 | TSHR (0.32) | TSHR | |
| SCHEMBL14642987 | 0.86 | TSHR (0.32) | TSHR | |
| SCHEMBL13494737 | 0.85 | CYP1A2 (0.39) | — | |
| SCHEMBL9944457 | 0.85 | — | — | |
| SCHEMBL11890981 | 0.83 | — | — | |
| SCHEMBL10286000 | 0.83 | — | — | |
| SCHEMBL414699 | 0.83 | — | — | |
| SCHEMBL11890983 | 0.83 | — | — | |
| SCHEMBL12869267 | 0.83 | — | — | |
| SCHEMBL174856 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228853-A1 | TEXTILE TEMPERATURE REGULATING AGENTS | DEVAN CHEMICALS NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-115394560-A | Low-temperature and high-pressure resistant electrolyte and preparation method and application thereof | 韶关东阳光电容器有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| EP-2855628-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | YALE UNIVERSITY | 2017-05-04 | — | — | US | disclosed |
| US-20160237302-A1 | WATERBORNE COMPOSITIONS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2016-08-18 | — | — | US | disclosed |
| WO-2015176978-A1 | PIPERIDINE-BASED STABILIZERS AND POLYMERS END-CAPPED WITH THE SAME | SOLVAY SPECIALTY POLYMERS USA, LLC (US) | 2015-11-26 | — | — | WO | disclosed |
| US-9193827-B2 | Poly(beta-amino alcohols), their preparation, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8454940-B2 | Mixtures comprising benzotriazoles and merocyanines | BASF SE (DE) | 2013-06-04 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-7985744-B2 | Administering 9,10-secopregna-5,7,10(19),16- tetraene derivative to a patient for treating skin diseases such as psoriasis | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| EP-2169021-A1 | Ink composition, inkjet recording method, and printed material | Fujifilm Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2166395-A1 | IMAGING DEVICE MANUFACTURING METHOD, IMAGING DEVICE AND OPTICAL ELEMENT | Konica Minolta Opto, Inc. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20040019023-A1 | Vitamin d derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1295871-A1 | VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | TSHR 3368/4885ALDH1A1 277/4885TDP1 1092/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | TSHR 3368/4885ALDH1A1 277/4885TDP1 1092/4885 |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | TSHR 3755/4885ALDH1A1 2905/4885TDP1 970/4885 |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | TSHR 4069/4885ALDH1A1 3482/4885TDP1 1604/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | TSHR 3368/4885ALDH1A1 277/4885TDP1 1092/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | TSHR 4832/4885ALDH1A1 2740/4885TDP1 1008/4885 |
| US-20040019023-A1 | Vitamin d derivatives | VDR, CYP24A1, CYP2R1 | TSHR 877/4885ALDH1A1 1023/4885TDP1 4775/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | TSHR 275/4885ALDH1A1 2335/4885TDP1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.